Courtesy of Benzinga.
Analysts at SunTrust Robinson Humphrey upgraded Amedisys Inc (NASDAQ: AMED) from Neutral to Buy.
The price target for Amedisys has been raised from $31.00 to $36.00.
Amedisys shares have gained 98.98 percent over the past 52 weeks, while the S&P 500 index has surged 10.18 percent in the same period.
Amedisys shares climbed 0.52 percent to close at $29.13 yesterday.
Latest Ratings for AMED
Date | Firm | Action | From | To |
---|---|---|---|---|
May 2015 | SunTrust Robinson Humphrey | Upgrades | Neutral | Buy |
Apr 2015 | Deutsche Bank | Maintains | Hold | |
Mar 2015 | Jefferies | Maintains | Hold |
View More Analyst Ratings for AMED
View the Latest Analyst Ratings
Posted-In: SunTrust Robinson HumphreyUpgrades Analyst Ratings